Enjoy complimentary customisation on priority with our Enterprise License!
The ALS treatment market size is estimated to grow by USD 663.7 million at a CAGR of 12.79% between 2023 and 2028. ALS, or amyotrophic lateral sclerosis, is a neurodegenerative disease. Market growth is driven by the rising incidence of ALS, unmet treatment needs, increased research funding for neurodegenerative disease therapeutics, aging population, and the development of novel drugs. Additionally The ALS treatment market addresses the urgent need for therapies to combat Lou Gehrig's disease and multiple sclerosis, motor neuron diseases characterized by nerve cell degeneration, genetic inheritance, and gene mutation, leading to glutamate accumulation and respiratory failure, affecting both men and women, with medications available through hospital pharmacies.
To learn more about this report, Request Free Sample
In the intravenous segment of the market, therapies such as Ursodoxicoltaurine are crucial for managing this neurodegenerative disorder. ALS affects the central nervous system, leading to the progressive degeneration of voluntary muscles. With a growing geriatric population, awareness about ALS and its impact on daily functions such as swallowing, breathing, speaking, walking, and hand movement is increasing. The prevalence of ALS varies, with both sporadic and familial types affecting populations worldwide. Despite advancements in immunotherapy drugs and drug therapies, the stationary lifestyle associated with ALS and the high cost of treatment remain significant challenges. Efforts to reduce infection rates and improve access to affordable treatments are essential for addressing the needs of ALS patients globally.
The market share by the intravenous segment will be significant during the forecast period. One of the primary factors for the growth of this market is the boost in the majority of amyotrophic lateral sclerosis. Several lateral sclerosis cases are sporadic, and 5%-10% of cases are familial. Every year, approximately 30,000 individuals are diagnosed in the US. Therefore, the increase in the prevalence of amyotrophic lateral sclerosis will boost the growth of the market during the forecast period.
Get a glance at the market contribution of various segments View a PDF Sample
The intravenous segment was valued at USD 333.55 million in 2018. Furthermore, advancements associated with motor neuron disease treatment are modest and are mostly outweighed by the inconvenience associated with receiving infusion therapy to patients who are mostly immobile and are on ventilation. Muscle relaxants and non-invasive ventilation are often utilized in conjunction with intravenous treatments to manage symptoms and improve patient comfort. Hence, these factors will drive the growth of the intravenous segment of the treatment market during the forecast period.
For more insights about the market research and growth share of various regions View PDF Sample now!
North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market in North America is driven by the US due to the existence of major market players such as Pfizer, Sangamo Therapeutics, and Celgene in the US and Canada. In addition, these players invest in marketing and patient awareness initiatives. Moreover, the US is anticipated to negatively impact the North American market due to the advanced healthcare infrastructure and availability of therapies for the market and the high disease prevalence and incidence. Canada is expected to emerge as the second-largest market due to increasing disease prevalence. Hence, such factors are expected to drive market growth in this region during the forecast period.
The market report witnessed significant attention due to its impact on nerve cells, spinal cord, and associated symptoms like paralysis, stiffness, and twitching. The difficulty of speaking, swallowing, and breathing underscore the urgency for effective treatments. FDA-approved drugs address symptoms, but side effects such as diarrhea, nausea, and upper respiratory infections pose concerns. With a rising demand for ALS drugs, untapped emerging markets offer growth opportunities supported by improved healthcare expenditure.
Early diagnosis through physical examinations and medical history reviews is crucial, emphasizing the importance of timely intervention. Despite delays and restraints, investments in ALS research and development, along with clinical trials, drive stable growth in the market segments. Rising awareness and evolving trends underscore the estimations for the ALS treatment market's future trajectory. There are multiple factors influencing the market. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
High research funding on the market is the key factor driving market growth. Funding for studies in neurogenerative diseases has been raised. For example, the EU joint program - Neurogenerative Disease Research (JPND), an innovative, collaborative research initiative established to tackle the challenges posed, is funding research scientists to conduct novel approaches that would help enhance the use of brain images for amyotrophic lateral sclerosis. This would cover a range of neurodegenerative diseases, including treatment.
Furthermore, in 2021, Neuratris, a research organization that deals in the research of innovative methods for the treatment of nervous system diseases, launched a new funding program for neurodegenerative diseases, including the market under which the organization has provided funds worth USD 55,000 to cover the cost of the project. Thus, high research funding on the market will drive the growth of the global Market during the forecast period.
An increase in the aging population is the primary trend shaping market growth. The aging population has been increasing across the globe with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn, raised the risk of developing neurological disorders such as Alzheimer's disease and Parkinson's disease.
Moreover, according to WHO, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. In Sub-Saharan Africa, neurological disorders are commonly found in the elderly; degenerative diseases such as dementia and PD were the most common diseases reported in the region. Therefore, an increase in the aging population will drive the growth of the global Market during the forecast period.
The availability of ineffective diagnosis methods is a challenge that affects market growth. Direct diagnostic tests are not open to select the presence of individuals. Instead, physicians opt to perform a series of tests, which help to distinguish from similar neurological diseases to arrive at an accurate diagnosis for amyotrophic lateral sclerosis. Furthermore, the initial symptoms can vary from person to person.
In addition, initial symptoms and MS are similar and may include muscle weakness, loss of coordination, and difficulty in moving limbs. Both diseases affect muscle and nerve function. It is difficult to analyze whether the symptoms are due to MS or amyotrophic lateral sclerosis. Thus, these factors are expected to restrain the growth of the global market during the forecast period.
The market growth and forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and trends report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth market forecasting strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Denali Therapeutics Inc.: The company offers to slow disease progression, including advancing clinical trials of investigational eIF2B activator treatment DNL343.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
The market is focused on combating this progressive neurodegenerative disease through various therapeutic approaches. ALS therapy aims to alleviate symptoms, slow disease progression, and improve the quality of life for patients. Current ALS treatments include medications like Riluzole and Edaravone, which have shown efficacy in delaying disease progression. Additionally, stem cell therapy holds promise for regenerative treatment options. The incidence rate of familial types of disorders can be managed through a combination of medication, physical therapy, and speech therapy.
Further, the market faces significant challenges despite advancements in Medical technology. While Stem cell therapies hold promise, there is less awareness and insubstantial treatment options available, leading to limited options for patients. Immunosuppressants are often used to manage symptoms, highlighting the need for more effective solutions. The reimbursement scenario further complicates access to care. Organizations like the Centers for Disease Control and Prevention (CDC) play a crucial role in raising awareness. Pharmaceutical companies like NeuroSense Therapeutics drive innovation, often supported by seed funding. Genetics and biomarkers are increasingly studied to understand the disease better and develop targeted therapies.
Moreover, the market addresses the urgent need for effective therapies to combat this neurodegenerative disorder, characterized by Lou Gehrig's disease, genetic inheritance, gene mutation, glutamate, and respiratory failure, impacting women and the geriatric population, with drug therapies available through online providers, Drug stores & retail pharmacies, particularly crucial for addressing the prevalence of ALS disease and awareness about ALS disease and its incidence rates, considering its sporadic type and familial types, while also focusing on the ability to swallow, breathe, speak, walk, and use hands, in the face of the challenges posed by stationary lifestyle and expensive treatment.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 12.79% |
|
Market growth 2024-2028 |
USD 663.7 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
12.48 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 42% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AB Science SA, Alkem Laboratories Ltd., Apotex Inc., Aquestive Therapeutics Inc., Biogen Inc., Brainstorm Cell Therapeutics Inc., CORESTEM Inc., Cytokinetics Inc., Denali Therapeutics Inc., Dr Reddys Laboratories Ltd., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Italfarmaco Holding SPA, Medindia Health, Mitsubishi Chemical Group Corp., Otsuka Holdings Co. Ltd., Revalesio Corp., Sanofi, Sun Pharmaceutical Industries Ltd., and Treeway BV |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
